Synopsis of recent research by authors named "Yi-Mi Wu"
- Yi-Mi Wu’s recent research predominantly focuses on the implications of cyclin-dependent kinase 12 (CDK12) alterations in metastatic castration-resistant prostate cancer (mCRPC), exploring how these genetic changes not only contribute to cancer progression but also expose potential vulnerabilities to targeted therapies.
- In a notable study, Wu demonstrated that biallelic loss of CDK12 is sufficient to induce pre-cancerous lesions and lymphocytic infiltration in murine models, highlighting the critical role CDK12 plays in prostate cancer development and associated immune responses.
- Additionally, Wu's work extends into precision oncology, analyzing genetic alterations in various cancers, such as myeloproliferative neoplasms and biliary tract cancers, advocating for genomic profiling to unearth actionable alterations that can guide more effective and personalized treatment strategies.
